La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Induction and depression of cytochrome P-450-dependent mixed-function oxidase by a cloned consensus α-interferon (IFN-αCON1) in the hamster

Identifieur interne : 001628 ( Istex/Curation ); précédent : 001627; suivant : 001629

Induction and depression of cytochrome P-450-dependent mixed-function oxidase by a cloned consensus α-interferon (IFN-αCON1) in the hamster

Auteurs : Shabbir M. Moochhala [Canada] ; Kenneth W. Renton [Canada] ; Nowell Stebbing [États-Unis]

Source :

RBID : ISTEX:65DA78E2925BF0F4B5114DDEC102E11CE45D0649

Abstract

A novel analogue of human α-interferon (IFN-αCON1) was tested for its ability to modify the hepatic cytochrome-P-450-dependent mixed-function oxidase system in the hamster. This cloned interferon was derived by selecting the most frequently observed amino acid sequences at each position in the known human α-interferon subtypes. IFN-αCON1 had a biphasic effect on cytochrome P-450 and related drug biotransformation in the hamster causing an initial increase followed by a significant depression. IFN-αCON1 also had a biphasic effect on cytochrome P-450 in the lung, adrenal and spleen but only a depressant effect in the kidney. This effect was not due to morphological damage and followed the species specificity for this type of interferon. Both the increase and the decrease in cytochrome P-450 could be prevented by the administration of the protein synthesis inhibitor puromycin. Various isozymes of cytochrome P-450 induced by phenobarbital, β-napthaflavone and clofibrate were also depressed by this interferon. The results presented in this report suggest that IFN-αCON1 interferon will likely depress drug biotransformation in humans because the antiviral effects and the “anticytochrome P-450” effect of interferons cannot be separated, and this interferon has antiviral properties in both hamster and human cells. Clinically relevant drug interactions may be common during the concomitant use of this interferon and other drugs that are metabolized by cytochrome P-450.

Url:
DOI: 10.1016/0006-2952(89)90383-3

Links toward previous steps (curation, corpus...)


Links to Exploration step

ISTEX:65DA78E2925BF0F4B5114DDEC102E11CE45D0649

Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Induction and depression of cytochrome P-450-dependent mixed-function oxidase by a cloned consensus α-interferon (IFN-αCON1) in the hamster</title>
<author>
<name sortKey="Moochhala, Shabbir M" sort="Moochhala, Shabbir M" uniqKey="Moochhala S" first="Shabbir M." last="Moochhala">Shabbir M. Moochhala</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada B3H 4H7</mods:affiliation>
<country>Canada</country>
<wicri:regionArea>Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Renton, Kenneth W" sort="Renton, Kenneth W" uniqKey="Renton K" first="Kenneth W." last="Renton">Kenneth W. Renton</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada B3H 4H7</mods:affiliation>
<country>Canada</country>
<wicri:regionArea>Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Stebbing, Nowell" sort="Stebbing, Nowell" uniqKey="Stebbing N" first="Nowell" last="Stebbing">Nowell Stebbing</name>
<affiliation wicri:level="1">
<mods:affiliation>Amgen Inc., Thousand Oaks, CA, U.S.A.</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Amgen Inc., Thousand Oaks, CA</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:65DA78E2925BF0F4B5114DDEC102E11CE45D0649</idno>
<date when="1989" year="1989">1989</date>
<idno type="doi">10.1016/0006-2952(89)90383-3</idno>
<idno type="url">https://api-v5.istex.fr/document/65DA78E2925BF0F4B5114DDEC102E11CE45D0649/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001628</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001628</idno>
<idno type="wicri:Area/Istex/Curation">001628</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">Induction and depression of cytochrome P-450-dependent mixed-function oxidase by a cloned consensus α-interferon (IFN-αCON1) in the hamster</title>
<author>
<name sortKey="Moochhala, Shabbir M" sort="Moochhala, Shabbir M" uniqKey="Moochhala S" first="Shabbir M." last="Moochhala">Shabbir M. Moochhala</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada B3H 4H7</mods:affiliation>
<country>Canada</country>
<wicri:regionArea>Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Renton, Kenneth W" sort="Renton, Kenneth W" uniqKey="Renton K" first="Kenneth W." last="Renton">Kenneth W. Renton</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada B3H 4H7</mods:affiliation>
<country>Canada</country>
<wicri:regionArea>Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Stebbing, Nowell" sort="Stebbing, Nowell" uniqKey="Stebbing N" first="Nowell" last="Stebbing">Nowell Stebbing</name>
<affiliation wicri:level="1">
<mods:affiliation>Amgen Inc., Thousand Oaks, CA, U.S.A.</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Amgen Inc., Thousand Oaks, CA</wicri:regionArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Biochemical Pharmacology</title>
<title level="j" type="abbrev">BCP</title>
<idno type="ISSN">0006-2952</idno>
<imprint>
<publisher>ELSEVIER</publisher>
<date type="published" when="1989">1989</date>
<biblScope unit="volume">38</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="439">439</biblScope>
<biblScope unit="page" to="447">447</biblScope>
</imprint>
<idno type="ISSN">0006-2952</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0006-2952</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass></textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">A novel analogue of human α-interferon (IFN-αCON1) was tested for its ability to modify the hepatic cytochrome-P-450-dependent mixed-function oxidase system in the hamster. This cloned interferon was derived by selecting the most frequently observed amino acid sequences at each position in the known human α-interferon subtypes. IFN-αCON1 had a biphasic effect on cytochrome P-450 and related drug biotransformation in the hamster causing an initial increase followed by a significant depression. IFN-αCON1 also had a biphasic effect on cytochrome P-450 in the lung, adrenal and spleen but only a depressant effect in the kidney. This effect was not due to morphological damage and followed the species specificity for this type of interferon. Both the increase and the decrease in cytochrome P-450 could be prevented by the administration of the protein synthesis inhibitor puromycin. Various isozymes of cytochrome P-450 induced by phenobarbital, β-napthaflavone and clofibrate were also depressed by this interferon. The results presented in this report suggest that IFN-αCON1 interferon will likely depress drug biotransformation in humans because the antiviral effects and the “anticytochrome P-450” effect of interferons cannot be separated, and this interferon has antiviral properties in both hamster and human cells. Clinically relevant drug interactions may be common during the concomitant use of this interferon and other drugs that are metabolized by cytochrome P-450.</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001628 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 001628 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Istex
   |étape=   Curation
   |type=    RBID
   |clé=     ISTEX:65DA78E2925BF0F4B5114DDEC102E11CE45D0649
   |texte=   Induction and depression of cytochrome P-450-dependent mixed-function oxidase by a cloned consensus α-interferon (IFN-αCON1) in the hamster
}}

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022